middle.news
Cynata finds extra backing for $750,000 placement as kidney trial advances
8:31am on Friday 13th of November, 2026 AEDT
•
Biotechnology
Read Story
Cynata finds extra backing for $750,000 placement as kidney trial advances
8:31am on Friday 13th of November, 2026 AEDT
Key Points
Proposed placement increased from approximately $550,000 to $750,000
Total potential proceeds from the placement and entitlement offer reach approximately $1.663 million before costs
Placement remains subject to shareholder approval at a general meeting expected in January 2027
NEREID trial's second cohort has completed treatment and is awaiting DSMB review
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE